Ovarian Cancer Radiomics Approach in CT Led Evaluation (NCT06817174) | Clinical Trial Compass
RecruitingNot Applicable
Ovarian Cancer Radiomics Approach in CT Led Evaluation
United Kingdom168 participantsStarted 2025-02-10
Plain-language summary
When patients have suspected or confirmed ovarian cancer standard treatment will involve surgery and chemotherapy. However, as with any treatment, it is challenging to predict treatment response in advance. Before treatment, all patients have a CT scan to describe where the cancer is in order to guide the treatment.
There is now a new way to analyse routine scans using advanced computing methods, which may give more information about the ovarian cancer. This is called radiomics which analyses features in scans that are not visible to the naked eye. Our group at Imperial College London has worked on developing radiomic models to better understand ovarian cancer.
This study aims to determine whether the information gained from this new approach would help us to tailor patient treatment plans to better meet the patient's individual needs, even more than done already. Furthermore, the aim is to understand how different types of ovarian cancer can correlate with the radiomic findings, which may help develop potential treatments in the future.
Who can participate
Age range
18 Years
Sex
FEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Written (signed and dated) informed consent
* Age 18 years or over
* Suspected or confirmed advanced epithelial ovarian cancer (FIGO stage 3B or more)
* Being considered for active anticancer treatment i.e. primary cytoreductive surgery followed by chemotherapy or neoadjuvant chemotherapy followed by interval cytoreductive surgery
* Evaluable baseline portal venous phase CT scan prior to surgical or medical treatment for ovarian cancer
* Disease visible on pre-treatment portal venous phase baseline CT scan (≥2cm)
Exclusion Criteria:
* Known contra-indication to CT with IV contrast (e.g. contrast allergy, renal failure, inability to lie flat);
* Unable to give informed consent;
* Known pregnancy;
* No visible disease \<2cm on portal venous phase baseline CT scan;
* Previous surgery for resection of an adnexal mass;
* Significant artefact on CT image for example from metal prostheses that precluded meaningful segmentation of visible disease
* Only fit for palliative care at initial presentation
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Comparison of CT-based Radiomics Models and Clinical Model in Predicting Progression-Free Survival Post-Cytoreductive Surgery in Ovarian Cancer
Timeframe: From enrolment to approximately 5 years after the last patient is enrolled, based on the final data capture at the end of follow-up.